| __timestamp | ACADIA Pharmaceuticals Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 10337679 |
| Thursday, January 1, 2015 | 90804000 | 18187286 |
| Friday, January 1, 2016 | 186456000 | 24758063 |
| Sunday, January 1, 2017 | 255062000 | 23666957 |
| Monday, January 1, 2018 | 265758000 | 30099855 |
| Tuesday, January 1, 2019 | 325638000 | 64947625 |
| Wednesday, January 1, 2020 | 388661000 | 186363444 |
| Friday, January 1, 2021 | 396028000 | 272611040 |
| Saturday, January 1, 2022 | 369090000 | 358782000 |
| Sunday, January 1, 2023 | 402466000 | 409864000 |
Unlocking the unknown
In the dynamic world of biopharmaceuticals, operational costs are pivotal in shaping a company's financial health. Over the past decade, Intra-Cellular Therapies, Inc. and ACADIA Pharmaceuticals Inc. have demonstrated intriguing trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ACADIA Pharmaceuticals saw a staggering 1,130% increase in SG&A expenses, peaking in 2023. Meanwhile, Intra-Cellular Therapies experienced an even more dramatic rise, with expenses surging by over 3,860% during the same period. This growth reflects strategic investments in marketing and administration, crucial for their competitive edge. Notably, both companies showed a significant uptick in expenses post-2019, aligning with industry-wide trends of increased spending on innovation and market expansion. As these companies continue to evolve, understanding their financial strategies offers valuable insights into the broader biopharma landscape.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
Breaking Down SG&A Expenses: AbbVie Inc. vs Intra-Cellular Therapies, Inc.
AbbVie Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs ACADIA Pharmaceuticals Inc. Trends and Insights
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs BioMarin Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated